<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978196</url>
  </required_header>
  <id_info>
    <org_study_id>2016KY220</org_study_id>
    <nct_id>NCT02978196</nct_id>
  </id_info>
  <brief_title>99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer</brief_title>
  <official_title>99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of 99m-Tc labeled anti-PD-L1 VHH for SPECT/CT diagnostic
      imaging of Non-Small Cell Lung Cancer and compare it with the existing gold standard &quot;biopsy
      PD-L1 detection&quot;. It is also to establish a new method of clinical diagnosis of NSCLC using
      99m-Tc labeled anti-PD-L1 VHH.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Assessment of NSCLC in 99m-Tc labeled anti-PD-L1 VHH SPECT/CT Scan</measure>
    <time_frame>1 year</time_frame>
    <description>Visual analysis will be carried out by 4 experienced nuclear medicine physicians to observe the uptake of 99m-Tc labeled anti-PD-L1 VHH in lung lesions.A 4 point system will be used to interpret the scans for abnormalities. It is categorised as such: score 0, no abnormal increased uptake; score 1, low increased uptake; score 2, moderate increased uptake; score 3, high increased uptake. The lesion will be considered positive for malignancy if the score is 2 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semiquantitative Assessment of Lung Lesions in 99m-Tc labeled anti-PD-L1 VHH SPECT/CT Scan</measure>
    <time_frame>1 year</time_frame>
    <description>Each patient will be administered 11.1 MBq/Kg of 99m-Tc labeled anti-PD-L1 VHH and the semiquantitative analysis of the standardized uptake values (SUV) will be performed in lung lesions. Higher level of PD-L1 expression (Tumor proportion score, TPS), higher SUV in tumor. No expression TPS &lt; 1%; Low expression TPS 1 - 49%; High expression TPS â‰¥ 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression levels</measure>
    <time_frame>1 year</time_frame>
    <description>The patients will be required to confirm the levels of PD-L1 expression using Human PD-L1 ELISA Kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reaction Report</measure>
    <time_frame>3 days</time_frame>
    <description>Monitor adverse events within 3 days after the injection and scanning to establish the safety of 99m-Tc labeled anti-PD-L1 VHH in patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New tumor detection</measure>
    <time_frame>1 year</time_frame>
    <description>SPECT/CT scans using 99m-Tc labeled anti-PD-L1 VHH may detect new tumor areas, which can be further proven by biopsy method in order to rule out any false positive results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PD-L1 Positive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients tested positive for PD-L1 expression (&gt;50%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-L1 Negative</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients tested negative for PD-L1 expression (&lt;1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PD-L1 expression detection in Lung cell</intervention_name>
    <description>Lung cell biopsies, PD-L1 expresser detection test, Blood test, SPECT/CT with 99m-Tc Labeled Anti-PD-L1 VHH</description>
    <arm_group_label>PD-L1 Positive</arm_group_label>
    <arm_group_label>PD-L1 Negative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for the participation in the
             study before any protocol-specific screening procedures are performed

          -  Male or female, aged 18-75 years old

          -  Previous diagnosis of non-small cell carcinoma, confirmed with pathology tests

          -  AST, ALT, BUN, Cr not more than double the normal values

          -  Patients with no current history of hepatitis A, hepatitis B, AIDS, tuberculosis and
             other infectious diseases

        Exclusion Criteria:

          -  Severe infection

          -  PD-L1 expression level undetermined

          -  Patients with pacemakers

          -  Pregnant and lactating women

          -  Investigators professional decision that the subject should not participate in this
             clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinhua Zhao, MD. PHD.</last_name>
    <phone>+8613311985588</phone>
    <email>zhaojinhua1963@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinhua Zhao, MD. PHD.</last_name>
      <phone>+8613311985588</phone>
      <email>zhaojinhua1963@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.</citation>
    <PMID>20516446</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Wu D, Shen L, Fang J. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015 Jul;6(4):534-8. doi: 10.1111/1759-7714.12247. Epub 2015 Mar 5.</citation>
    <PMID>26273411</PMID>
  </reference>
  <reference>
    <citation>Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, Boerman OC. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res. 2015 Jul 15;75(14):2928-36. doi: 10.1158/0008-5472.CAN-14-3477. Epub 2015 May 14.</citation>
    <PMID>25977331</PMID>
  </reference>
  <reference>
    <citation>Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res. 2016 Jan 15;76(2):472-9. doi: 10.1158/0008-5472.CAN-15-2141. Epub 2015 Nov 10.</citation>
    <PMID>26554829</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jinhua Zhao</investigator_full_name>
    <investigator_title>Director Department of Nuclear Medicine, Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

